Next Article in Journal
Classical and Alternative Activation of Rat Microglia Treated with Ultrapure Porphyromonas gingivalis Lipopolysaccharide In Vitro
Previous Article in Journal
Aflatoxin Reduction in Maize by Industrial-Scale Cleaning Solutions
Previous Article in Special Issue
Treatment of Blepharospasm and Oromandibular Dystonia with Botulinum Toxins
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 12
Issue 5
10.3390/toxins12050332
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia

by
Lauren L. Spiegel
,
Jill L. Ostrem
and
Ian O. Bledsoe
*
Movement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USA
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(5), 332; https://doi.org/10.3390/toxins12050332
Submission received: 20 March 2020 / Revised: 1 May 2020 / Accepted: 13 May 2020 / Published: 17 May 2020
(This article belongs to the Special Issue Treatment of Dystonia with Botulinum Toxins)
Versions Notes

Abstract

In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area.
Keywords: botulinum toxin; dystonia; cervical dystonia; blepharospasm; FDA botulinum toxin; dystonia; cervical dystonia; blepharospasm; FDA

Share and Cite

MDPI and ACS Style

Spiegel, L.L.; Ostrem, J.L.; Bledsoe, I.O. FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins 2020, 12, 332. https://doi.org/10.3390/toxins12050332

AMA Style

Spiegel LL, Ostrem JL, Bledsoe IO. FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins. 2020; 12(5):332. https://doi.org/10.3390/toxins12050332

Chicago/Turabian Style

Spiegel, Lauren L., Jill L. Ostrem, and Ian O. Bledsoe. 2020. "FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia" Toxins 12, no. 5: 332. https://doi.org/10.3390/toxins12050332

APA Style

Spiegel, L. L., Ostrem, J. L., & Bledsoe, I. O. (2020). FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia. Toxins, 12(5), 332. https://doi.org/10.3390/toxins12050332

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop